Capricor sues Japanese partner over botched Duchenne therapy launch and pricing concerns

Capricor Therapeutics has filed a lawsuit against its Japanese collaborator Nippon Shinyaku and its subsidiary NS Pharma. The biotech alleges the partners mishandled preparations for the launch of deramiocel, its cell‑based treatment for Duchenne muscular dystrophy.

According to the complaint, the launch missteps include inadequate planning and a pricing structure that could make the therapy unaffordable for many patients. Capricor argues that these actions jeopardize patient access to the promising therapy.

The dispute highlights the challenges of bringing advanced cell therapies to market, especially when multiple parties are involved in development and commercialization. The lawsuit underscores the importance of clear launch strategies and pricing models in the biotech sector.